CLLS — Cellectis S.A.

Cellectis Q2 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of June 30, 2025, Cellectis reported cash, cash equivalents, and fixed-term deposits of $230 million, down from $264 million at the end of 2024. The decrease of $33.2 million was attributed to operational expenses, including $23.2 million to suppliers and $23.6 million for wages and bonuses.
• Net Loss: Specific figures regarding the consolidated net loss attributable to shareholders for the first half of 2025 were not disclosed but are available in the press release.

2. Strategic Updates and Business Highlights

• Clinical Trials: Cellectis is advancing its clinical programs, particularly:
  • lasme-cel (UCART22): Completed end of Phase I discussions with the FDA and EMA, with plans to initiate a pivotal Phase II trial in the second half of 2025.
  • NatHaLi-01 Study: Ongoing evaluation of eti-cel (UCART20x22) in non-Hodgkin lymphoma, with data expected to be presented in late 2025.
• Partnerships: Continued collaboration with AstraZeneca on three cell and gene therapy programs.
• Board Changes: André Muller was appointed to the Board of Directors, succeeding Pierre Bastid and Axel-Sven Malkomes.

3. Forward Guidance and Outlook

• R&D Day: Scheduled for October 16, 2025, where Cellectis will present Phase I data for lasme-cel and outline the late-stage development strategy.
• Cash Runway: The company is well-positioned financially, with sufficient cash to fund operations into the second half of 2027, including pivotal studies for lasme-cel and eti-cel.

4. Bad News, Challenges, or Points of Concern

• Arbitration with Servier: Cellectis is engaged in arbitration regarding a licensing agreement with Servier, which could impact the development of CD19 products. The decision is expected by December 15, 2025.
• Market Conditions: The biotech sector remains challenging, which may affect funding and operational dynamics.
• Regulatory Risks: While recent interactions with the FDA and EMA were positive, any unforeseen regulatory hurdles could impact clinical trial timelines.

5. Notable Q&A Insights

• Servier Arbitration: CEO Andre Choulika emphasized the uncertainty surrounding the arbitration outcomes but expressed confidence in Cellectis' position.
• Pivotal Trial Design: Dr. Adrian Kilcoyne confirmed alignment with regulatory authorities on endpoints and study design for lasme-cel, indicating a clear path forward.
• Infection Risk Mitigation: The company has established protocols to address potential infection risks associated with lymphodepletion in trials.
• Competitive Landscape: Discussions highlighted the differentiation of eti-cel from autologous CAR-T therapies, particularly its targeting strategy and off-the-shelf nature.

Overall, Cellectis is making significant progress in its clinical programs while navigating challenges related to partnerships and market conditions. The upcoming R&D Day is anticipated to provide further clarity on their development strategies and financial outlook.